At a glance
Selected controlled studies examine visceral fat in defined populations and liver fat in people with HIV and steatosis. Imaging and biopsy findings add clinical depth but do not establish a general weight-loss or strength benefit.
Identity & scope
Tesamorelin is the defined GHRH analogue studied in the trials below. Clinical products and research-catalogue formats are separate specifications.
What the research shows
- The studies distinguish visceral from subcutaneous fat, rather than treating all weight-related outcomes as equivalent.
- The extension phase shows why persistence after stopping is a separate question from a response during treatment.
Critical interpretation
Fat compartments and durability matter
The abdominal-fat studies distinguish visceral adipose tissue from subcutaneous fat. A reduction in one compartment is a more precise result than a general statement about weight loss. The blinded extension also shows that a response maintained during treatment is different from a lasting response after discontinuation: initial visceral-fat improvement was rapidly lost after switching to placebo. Neither observation establishes improved strength or prevention of cardiovascular events. [1] [2]
Liver-fat research adds clinical depth, with a defined boundary
The HIV/liver-steatosis trial used blinded imaging and paired biopsies, giving a stronger basis for its liver-fat endpoint than hormone measurements alone. The fibrosis-progression signal is informative, but existing fibrosis did not significantly improve and the trial was not designed to establish definitive treatment of steatohepatitis. Mean glucose measures also cannot capture every participant’s experience: two treated participants discontinued for hyperglycaemia. This supports a population- and endpoint-specific interpretation, rather than a broad claim of liver protection or metabolic safety. [3]
Measuring metabolites is an analytical outcome
This study adds evidence about detecting the peptide and its degradation products in biological matrices. The endpoint concerns assay performance, so it should be read separately from randomized clinical studies of body composition or liver fat. [4]
Limitations & uncertainties
- No general athletic-performance benefit is established here.
- Trial-product results do not validate nasal products or establish the identity, purity or effectiveness of catalogue materials.
Open research questions
- Which population and fat compartment does a cited result concern?
- Are outcomes sustained after the intervention ends, and were clinically important outcomes directly measured?
Selected papers & source records
Download bibliography1. Metabolic effects of a growth hormone-releasing factor in obese subjects with reduced growth hormone secretion: a randomized controlled trial (opens in a new tab)
Makimura H, Feldpausch MN, Rope AM, et al. (2012). Journal of Clinical Endocrinology & Metabolism. DOI: 10.1210/jc.2012-2794 (opens in a new tab) · PMID 23015655
- Design & population
- Randomized double-blind placebo-controlled 12-month study in 60 adults with abdominal obesity and reduced GH secretion.
- What the study found
- Tesamorelin reduced visceral abdominal fat relative to placebo. Subcutaneous abdominal fat did not change significantly; IGF-I increased.
- Limits on interpretation
- Selected participants with reduced GH secretion and surrogate metabolic endpoints. The trial does not establish general weight-loss, strength or cardiovascular-event benefits.
Original source (opens in a new tab) · Full text at publisher / archive (opens in a new tab)
2. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension (opens in a new tab)
Falutz J, Potvin D, Mamputu JC, et al. (2010). Journal of Acquired Immune Deficiency Syndromes. DOI: 10.1097/QAI.0b013e3181cbdaff (opens in a new tab) · PMID 20101189
- Design & population
- Randomized placebo-controlled trial in 404 people with HIV, antiretroviral treatment and excess abdominal fat, followed by a blinded extension.
- What the study found
- Visceral fat decreased during treatment. Initial improvement was rapidly lost in participants switched to placebo during the extension.
- Limits on interpretation
- Findings concern a specific clinical population and trial product. They do not demonstrate lasting effects after stopping or validate research-catalogue formats.
3. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial (opens in a new tab)
Stanley TL, Fourman LT, Feldpausch MN, et al. (2019). The Lancet HIV. DOI: 10.1016/S2352-3018(19)30338-8 (opens in a new tab) · PMID 31611038
- Design & population
- Twelve-month randomized placebo-controlled trial in people with HIV and defined liver steatosis. Liver fat was the primary endpoint; imaging, liver biopsies and safety assessments were used.
- What the study found
- Liver fat decreased more with tesamorelin. Fewer participants had fibrosis progression, but existing fibrosis did not significantly improve.
- Limits on interpretation
- The study was designed for liver-fat change, not definitive treatment of steatohepatitis or long-term clinical events. Two treated participants stopped for worsening hyperglycaemia despite neutral mean glucose results.
Original source (opens in a new tab) · Full text at publisher / archive (opens in a new tab)
4. Detecting GHRH Analogue Tesamorelin and Its Metabolites in Post-Administration Human Urine and Serum Using LC-HRMS/MS (opens in a new tab)
Colpaert T, Miller G, Goodrum J, et al. (2026). Drug Testing and Analysis. DOI: 10.1002/dta.70189 (opens in a new tab) · PMID 43013893
- Design & population
- Mass spectrometry method study using urine and serum from six volunteers given a defined clinical preparation, plus a separate serum metabolism experiment.
- What the study found
- The authors identified five previously unreported metabolites. They reported different detection performance across the urine and serum samples.
- Limits on interpretation
- Small method study using one preparation. PubMed and university repository abstracts consulted. The findings do not measure treatment benefit or verify a commercial batch.
Search & review scope
Targeted web searches of PubMed-indexed primary research and original journal records. Selected abstracts and citation metadata were checked; full-text sections were consulted for the records explicitly labelled full-text. Retrieved records and targeted notice searches were also checked for visible corrections or retractions. Added a targeted November 2026 analytical source check.. Checked 16 November 2026.
Selected primary research relevant to the named compound, its molecular specification and the endpoints described below. Checked the PubMed abstract and Ghent University record for the new analytical method.
Narrative selection, not a systematic review, comprehensive safety assessment or complete retraction audit. PubMed/PMC full-text access was intermittent. An abstract or selected-section review cannot replace appraisal of the complete methods, supplements and underlying data. Absence from this selection does not establish absence of research. The new analytical source was reviewed at abstract level.
Recorded search terms
- 23015655 tesamorelin
- "Metabolic effects of a growth hormone-releasing factor in obese subjects"
- site.pubmed.ncbi.nlm.nih.gov tesamorelin HIV abdominal fat 18057338
- site.pubmed.ncbi.nlm.nih.gov tesamorelin nonalcoholic fatty liver randomized 2019
- "31611038" tesamorelin authors DOI
- PMID 43013893 / DOI 10.1002/dta.70189
Read the collection’s methods and editorial limits. For formal research, assess and cite the original paper.
Cite this review
HeartPep. Tesamorelin: literature review. HeartPep literature library. Reviewed 16 November 2026. https://heartpep.com/us/research/library/tesamorelin.
HeartPep is the commercial publisher of this secondary summary. It is not a peer-reviewed primary paper. Cite the original studies for their findings.
Buy from HeartPep.com
Laboratory research only. Not for human or veterinary use.